Unit 1612: Pharmacoeconomics

1. Introduction to Pharmacoeconomics

1.1 Definition and Scope

• Overview of pharmacoeconomics
• Importance in healthcare decision-making

1.2 Key Principles and Concepts

• Economic evaluation in healthcare
• Role of cost and outcomes
• Stakeholders involved

2. Types of Pharmacoeconomic Studies

2.1 Cost-Minimization Analysis (CMA)

• Definition and use cases
• Assumptions and limitations

2.2 Cost-Effectiveness Analysis (CEA)

• Measuring costs vs. clinical outcomes
• Incremental cost-effectiveness ratio (ICER)

2.3 Cost-Utility Analysis (CUA)

• Incorporation of quality-adjusted life years (QALYs)
• Utility measurement methods

2.4 Cost-Benefit Analysis (CBA)

• Converting outcomes to monetary values
• Benefits and challenges

2.5 Comparison and Applications

• Choosing appropriate study types
• Examples from healthcare settings

3. Pharmacoeconomic Evaluation Methods

3.1 Modeling Techniques

• Decision trees
• Markov models
• Simulation models

3.2 Sensitivity Analysis

• Purpose and types (one-way, multi-way, probabilistic)
• Interpretation of results

3.3 Discounting

• Time preference and discount rates
• Applying discounting to costs and outcomes

3.4 Budget Impact Analysis

• Purpose and methodology
• Impact on healthcare budgets

4. Pharmacoeconomic Outcomes

4.1 Cost Outcomes

• Direct costs (medical, non-medical)
• Indirect costs (productivity loss, absenteeism)

4.2 Clinical Outcomes

• Mortality, morbidity, disease progression
• Surrogate endpoints

4.3 Quality of Life Outcomes

• Health-related quality of life (HRQoL) measures
• Instruments (e.g., EQ-5D, SF-36)

5. Pharmacoeconomic Data Sources

5.1 Clinical Trials

• Randomized controlled trials (RCTs)
• Strengths and limitations

5.2 Observational Studies

• Cohort, case-control, registry data
• Real-world evidence

5.3 Healthcare Databases

• Administrative claims data
• Electronic health records

5.4 Systematic Reviews and Meta-Analyses

• Aggregating evidence
• Role in pharmacoeconomic modeling

6. Pharmacoeconomic Challenges and Limitations

6.1 Data Quality and Availability

• Missing data, bias, and variability

6.2 Generalizability and Transferability

• Population differences
• Healthcare system variability

6.3 Uncertainty and Variability

• Handling uncertainty in models

6.4 Ethical Considerations

• Equity and access
• Transparency and conflicts of interest

7. Pharmacoeconomics in Drug Pricing and Reimbursement

7.1 Role in Pricing Decisions

• Value-based pricing
• Negotiation with payers

7.2 Market Access Implications

• Formulary inclusion/exclusion
• Reimbursement policies

7.3 Impact on Healthcare Policy

• Policy frameworks
• Incentives and regulation

8. Pharmacoeconomics in Health Technology Assessment (HTA)

8.1 Purpose and Scope of HTA

• Integration of clinical, economic, social aspects

8.2 Role of Pharmacoeconomic Evaluations

• Informing adoption and reimbursement
• Case studies

8.3 HTA Processes and Stakeholders

• Agencies and guidelines
• Public engagement

9. Global Perspectives in Pharmacoeconomics

9.1 Regional Approaches

• North America, Europe, Asia-Pacific differences
• Regulatory environments

9.2 International Collaboration and Standards

• ISPOR, WHO guidelines
• Harmonization efforts

9.3 Implications for Global Healthcare Systems

• Access disparities
• Adapting methods for local contexts